There is one clinical trial.
Bronchiolitis is a significant cause of morbidity and hospitalization in children, accounting for approximately 125,000 hospitalizations per year in the U.S. Recently, genetic variations of the β2-adrenergic receptor (β2-AR) have been shown to influence response to β2-AR agonist therapy in children with asthma. We suspect that genetic variations of the β2-AR also affect response to β2-AR agonist therapy in children with bronchiolitis.
The next most common polymorphism of the β2-AR gene, glutamine to glutamic acid at position 27 (Glu27Gln), may be associated with the development of asthma and airway hyperresponsiveness, but these relationships are less clear. --- Glu27Gln ---
Description: The primary end point is change in lung resistance following a single dose of inhaled b2-AR agonist therapy (albuterol).Measure: Change in lung resistance Time: Immediate
Description: To assess the change in lung compliance following a single dose of inhaled b2-AR agonist therapy (albuterol)Measure: Change in lung compliance Time: Duration of hospitalization
Description: To compare duration of mechanical ventilation and ICU hospital length of stay by genotypeMeasure: Comparison by genotype Time: Duration of Hospitalization